138 related articles for article (PubMed ID: 8663052)
21. Structure of the agonist-bound neurotensin receptor.
White JF; Noinaj N; Shibata Y; Love J; Kloss B; Xu F; Gvozdenovic-Jeremic J; Shah P; Shiloach J; Tate CG; Grisshammer R
Nature; 2012 Oct; 490(7421):508-13. PubMed ID: 23051748
[TBL] [Abstract][Full Text] [Related]
22. Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling.
Unson CG; Wu CR; Jiang Y; Yoo B; Cheung C; Sakmar TP; Merrifield RB
Biochemistry; 2002 Oct; 41(39):11795-803. PubMed ID: 12269822
[TBL] [Abstract][Full Text] [Related]
23. Optimization and
Bumbak F; Keen AC; Gunn NJ; Gooley PR; Bathgate RAD; Scott DJ
Biochim Biophys Acta Biomembr; 2018 Jun; 1860(6):1372-1383. PubMed ID: 29596791
[TBL] [Abstract][Full Text] [Related]
24. Binding chemistry and molecular heterogeneity of neurotensin binding protein(s)/receptor in adult chicken tissues.
Mitra SP
Indian J Biochem Biophys; 2013 Dec; 50(6):511-20. PubMed ID: 24772976
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.
Hausmann H; Richters A; Kreienkamp HJ; Meyerhof W; Mattes H; Lederis K; Zwiers H; Richter D
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):6907-12. PubMed ID: 8692917
[TBL] [Abstract][Full Text] [Related]
26. Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
Munck Petersen C; Nielsen MS; Jacobsen C; Tauris J; Jacobsen L; Gliemann J; Moestrup SK; Madsen P
EMBO J; 1999 Feb; 18(3):595-604. PubMed ID: 9927419
[TBL] [Abstract][Full Text] [Related]
27. Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells.
Chiang N; Kan WM; Tai HH
Arch Biochem Biophys; 1996 Oct; 334(1):9-17. PubMed ID: 8837733
[TBL] [Abstract][Full Text] [Related]
28. Thermostabilization of the neurotensin receptor NTS1.
Shibata Y; White JF; Serrano-Vega MJ; Magnani F; Aloia AL; Grisshammer R; Tate CG
J Mol Biol; 2009 Jul; 390(2):262-77. PubMed ID: 19422831
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues.
Heyl DL; Sefler AM; He JX; Sawyer TK; Wustrow DJ; Akunne HC; Davis MD; Pugsley TA; Heffner TG; Corbin AE
Int J Pept Protein Res; 1994 Sep; 44(3):233-8. PubMed ID: 7822099
[TBL] [Abstract][Full Text] [Related]
30. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants.
Monnot C; Bihoreau C; Conchon S; Curnow KM; Corvol P; Clauser E
J Biol Chem; 1996 Jan; 271(3):1507-13. PubMed ID: 8576145
[TBL] [Abstract][Full Text] [Related]
31. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
Zhao MM; Hwa J; Perez DM
Mol Pharmacol; 1996 Nov; 50(5):1118-26. PubMed ID: 8913343
[TBL] [Abstract][Full Text] [Related]
32. Structural insight into the specific interaction between murine SHPS-1/SIRP alpha and its ligand CD47.
Nakaishi A; Hirose M; Yoshimura M; Oneyama C; Saito K; Kuki N; Matsuda M; Honma N; Ohnishi H; Matozaki T; Okada M; Nakagawa A
J Mol Biol; 2008 Jan; 375(3):650-60. PubMed ID: 18045614
[TBL] [Abstract][Full Text] [Related]
33. Pivotal role of an aspartate residue in sodium sensitivity and coupling to G proteins of neurotensin receptors.
Martin S; Botto JM; Vincent JP; Mazella J
Mol Pharmacol; 1999 Feb; 55(2):210-5. PubMed ID: 9927610
[TBL] [Abstract][Full Text] [Related]
34. Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors. Identification by site-directed mutagenesis.
Kobayashi T; Ushikubi F; Narumiya S
J Biol Chem; 2000 Aug; 275(32):24294-303. PubMed ID: 10827082
[TBL] [Abstract][Full Text] [Related]
35. Impaired G protein coupling of the neurotensin receptor 1 by mutations in extracellular loop 3.
Richard F; Barroso S; Nicolas-Ethève D; Kitabgi P; Labbé-Jullié C
Eur J Pharmacol; 2001 Dec; 433(1):63-71. PubMed ID: 11755135
[TBL] [Abstract][Full Text] [Related]
36. Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.
Einsiedel J; Hübner H; Hervet M; Härterich S; Koschatzky S; Gmeiner P
Bioorg Med Chem Lett; 2008 Mar; 18(6):2013-8. PubMed ID: 18276136
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine.
Lundquist JT; Dix TA
J Med Chem; 1999 Nov; 42(23):4914-8. PubMed ID: 10579853
[TBL] [Abstract][Full Text] [Related]
38. The signaling signature of the neurotensin type 1 receptor with endogenous ligands.
Besserer-Offroy É; Brouillette RL; Lavenus S; Froehlich U; Brumwell A; Murza A; Longpré JM; Marsault É; Grandbois M; Sarret P; Leduc R
Eur J Pharmacol; 2017 Jun; 805():1-13. PubMed ID: 28341345
[TBL] [Abstract][Full Text] [Related]
39. Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line.
Martin S; Navarro V; Vincent JP; Mazella J
Gastroenterology; 2002 Oct; 123(4):1135-43. PubMed ID: 12360476
[TBL] [Abstract][Full Text] [Related]
40. Receptor mediated internalization of neurotensin in transfected Chinese hamster ovary cells.
Hermans E; Octave JN; Maloteaux JM
Biochem Pharmacol; 1994 Jan; 47(1):89-91. PubMed ID: 8311847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
